October 13, 2022 Bio/Pharma/CRO M&A, Partnerships

Cytel to acquire SDS Life Science and SDS MedteQ to enhance and expand thought-leadership in strategic therapeutic development 

Waltham, MA, October 13, 2022 – Cytel Inc., provider of quantitative insights and health data analytics to leaders in life sciences, has entered into an agreement to acquire SDS Life Science AB and SDS MedteQ AB. The move will add new global talent to Cytel’s Strategic Consulting group and bring additional expertise and capabilities for the... Read more

October 12, 2022 Bio/Pharma/CRO Molecular Spectroscopy PR/Corporate

Agilent Opens Center of Excellence for Dissolution Products

SANTA CLARA, Calif., October 12, 2022  Agilent Technologies Inc. (NYSE: A) today announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the core of Agilent’s dissolution business, including research and development, quality, support, applications, marketing, and more. This investment allows all Agilent dissolution... Read more

September 13, 2022 Bio/Pharma/CRO Clinical Research/Diagn.

GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease

Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [18F]flurpiridaz PET compared to SPECT Myocardial Perfusion Imaging (MPI) With a half-life roughly 12 times longer than currently approved cardiac PET radiotracers, if approved,... Read more